RecallDepth
Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. NDC: 82009-030-10

This recall is currently active, issued September 17, 2025. It was issued by Breckenridge Pharmaceutical, Inc..

Company
Breckenridge Pharmaceutical, Inc.
Recall Initiated
August 8, 2025
Posted
September 17, 2025
Recall Number
D-0621-2025
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
3,591 bottles
Firm Location
Berkeley Heights, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.

Distribution

AZ, IN, NJ

Lot / Code Info

Lot 240927C, Exp 04/30/2027

More recalls by Breckenridge Pharmaceutical, Inc.

View all recalls by this company →

Other recent Class II Drug recalls